|
Submission of articles
Manuscripts must be submitted electronically at: https://mc04.manuscriptcentral.com/infectio, where the information required fortheir submission can be found. The use of this resourceenables the state of the manuscript to be followed throughthe page indicated. The text of the manuscript, with the Abstract, Keywords, Literature References, Tables and their Legends and Figurefootnotes, will be included in a single file, while each one ofthe figures will be sent in separate files. These documentswill be saved in the “Attach Files” section.
You may consult the general instructions in its tutorial for authors:
http://mchelp.manuscriptcentral.com/gethelpnow/
Specific guidelines for each section
Original Articles: These are works on clinical or experimental research, in pharmacology, etiology, physiopathology, anatomopathological, zoonosis, epidemiology, diagnosis, treatment, clinical guidelines and expert´s consensusin human infectious diseases that may be considered of use andinterest by our scientific community. The maximumrecommended length of the text will be 1.500 words inpages DIN-A4, without including the Abstract and Keywords and up to amaximum of 30 Literature References. Up to 6 figures or tables will also be allowed. For the preparation ofcontrolled clinical trials, the CONSORT guidelines must befollowed (JAMA. 1996;276:637-9). Available at: http://www.consort-statement.org/. Original articles should be structured in subsections: Introduction, Material and method, Results Discussion and References. If human subjects were included a statement about how informed consent was obtained should be included. Clinical guidelines can have a greater number of pages and should follow the recommendation of NICE organization http://www.nice.org.uk/guidelinesmanual or from the Colombia Minister of Health:
http://www.minsalud.gov.co/salud/Documents/Gu%C3%ADa%20Metodol%C3%B3gica%20para%20la%20elaboraci%C3%B3n%20de%20gu%C3%ADas.pdf
Expert´s consensus can be justified if not enough evidence on a topic is available and can follow the recommendations of the American Journal of Managed Care:
http://www.ajmc.com/publications/issue/1998/1998-07-vol4-n7/Jul98-1122p1023-1029/
For guidelines and expert´s consensus abstracts should be of 200 words unstructured and a maximal length of 5.000 words and up to 6 tables and 6 figures. It should have a maximum of 80 references
Reviews: Contributions will be included which give a complete update on any topic of interest on infectious diseasesand could be invited or unsolicited;any person interested in contributing to this section should contact any member of the Editorial Committee beforehand. Reviews should describe literature search strategy, including search terms, period of inclusion and criteria for articles selection. Metanalysis on interventions should follow the Cochrane collaboration recommendations:
http://methods.cochrane.org/sites/methods.cochrane.org/files/MECIR%20Reporting%20standards%201.0.pdf
Reviewswill have a maximum of 5.000 words in DIN-A4 pages of text, without includingthe corresponding Abstract of 150 words and Key Words, and up to amaximum of 80 literature references. Up to6 figures or tables will also be allowed in the text.
Clinical cases reports: Report of unusual cases or report of adverse events, related to human infectious diseases. Abstract of 150 words unstructured, maximum length of 1.500 words and with subsections: Introduction, case description and discussion. Up to 10 references and one table or figure will be allowed.
Letters to the Editor: This section will contain objections and commentson articles published in the last two numbers of our journal.The maximum length of the text must not exceed1.000 words, will not have an abstract and will containup to a maximum of 5 authors and 10 literature references. The numberof signatories is limited to four. Letters about articlespreviously published in the Journal will have priority inbeing published, as well as the right to reply. They will besubmitted to the author of the original article, who will be able to answer in a letter of similar length within a periodof one month. The letter and the reply will be publishedtogether.
Editorials (only for Editorial Committee or by invitation):Will cover states of opinion on aspects associated withhuman infectious diseases in general, and specifically related to topicsin the Infectio journal, and preferably in connectionwith any of the articles published in the same Journalissue. These works will be commissioned by theJournal. Its length will be a maximum of1.000 words and maximum 10 references, and with only one author; in exceptionalcases two authors may be allowed or by all the editorial committee. It will not be dividedinto sub-sections. The use of tables and figures will be atthe discretion of the Executive Committee.
COVER LETTER
All manuscripts must beaccompanied by a mandatory cover letter, which will be included in the “Attach Files” section of the EES, in which it will indicate:
1) the Journal section in which you wish to publish the article;
2) the declaration that the work is original and is not in any evaluation process by another scientific journal;
3) explanation, in a maximum of one paragraph, of what is the original contribution and the relevance of the work in the Journal;
4) that the Instructions for Authors and the ethical responsibilities have been taken into accounts, and should include a statement that all signing authors fulfil the authorship requirements, that agrees with present version of the manuscript and that all have declared whether or not there are conflicts of interest, both in the“Title Page” (Read the “Funding and Conflict of Interests” section included in these Guidelines);
5) The list of scientific events, congress or symposium or working papers where preliminary or partial results have been presented. In the event that part of the article has been published previously in another journal (Redundant or Duplicate publication), the details should be specified here and declare that you are in possession of the necessary permissions of its author and its editor (Read the section “Guarantees and transfer of intellectual property rights”).
The authors can propose persons who they consider qualified to make a critical review of the manuscript. The proposed reviewers must not have been collaborators or co-authors in the 3 previous years and must not have contributed by substantially reviewing the manuscript.
Obligations of the author
Ethical considerations
Protection of persons and animals. When experiments that have been performed in humans are described,it should be indicated whether these procedures wereperformed in accordance with the ethical guidelines ofthe corresponding ethics committee (institutional orregional) and the Declaration of Helsinki of 1975, withthe current review, available at:
http://www.wma.net/en/30publications/10policies/b3/
When experiments withanimals are described, it should be indicated that theguidelines of the institution or international research councilor national regulations were followed for the care and useof laboratory animals.
Confidentiality. The authors are responsible for followingthe protocols established by their respective health carecenters to access the data of the clinical histories in orderto be able to make this type of research/information for thecommunity and thus they should declare having compliedwith this requirement. The author is required to assure thatthe requirement of having informed all the patients includedin the study and that he/she has a signed document fromthem stating that they have received sufficient informationand that their written informed consent to participate init has been obtained. The authors should mention in thesection “Methods” that the procedures used in the patientsand controls have been conducted after obtaining aninformed consent or that Ethic Committee or Institutional Board Review Commission has determined that it is not needed in the case of retrospective studies based on clinical charts data or studies using serum bank or laboratory clinical samples. In all cases the date and number of act of the Commission should be mentioned in the material and method section.
Privacy. The author (s) is (are) responsible (s) to guarantee the right to privacy of the patients, protecting their identity inthe writing of the article and images. Do not use names, initials or clinical history numbers of the hospital (or anyother type of irrelevant data for the investigation thatcould identify the patient) in either the text or photographs unless such information is essential for the scientificpurposes. In such case, they could be used in the article aslong as the patient or his/her parent or guardian has givenwritten informed consent for its publication. The authorsare responsible for obtaining the written informed consent, authorizing its publication, reproduction and disclosure onpaper and open access in internet.
Financing. The authors must declare the origin of any financingreceived. They should state if the investigation has receivedany financing from the US National Institutes of Health orif any of the authors belong to the Howard Hughes MedicalInstitute.
Authorship.The list of authors should only include those persons whohave made an intellectual contribution to the developmentof the study. Having helped in data collection or some studyprocedure is not on its own right sufficient to warrant being an author (read “Acknowledgments”). In general, in order to be included as an author, an individual should have:
1. Participated in the design and development of the study, the data collection, analysis and interpretation of thework data leading to the article in question.
2. Participated in the drafting of the text and its revisions.
3. Have approved the version that is finally published.
In the case of group authorship, the names of the writersor those responsible for the manuscript followed by “and theGroup, etc.” should be included when all the group membersare considered to be co-authors of the work. If it is desired toinclude the name of the group, although not all its membersare considered as co-authors, the formula that should beused is to mention the responsible authors followed by “onbehalf of the Group...” or “by the Group ....” In any case, thenames and institutions of the group members should be included in an annex at the end of the manuscript.
The authors should state that these criteria have beenmet both on the title page and in the Add/Edit/RemoveAuthor section and this statement should be included in the cover letter.
They should declare that they have read and approvedthe manuscript and that the requirements for the authorshiphave been met.
Infectio cannot be heldresponsible for any possible conflicts arising from authorshipof the manuscripts published in the journal.
Conflict of interests.There is a conflict of interest when the author had/haseconomic or personal relationship that might have biasedor inappropriately influenced his or her acts. The potential conflict of interest exists regardless of whether or notthe interested parties consider that these relationshipsinfluenced their scientific judgment. The authors must describe any financial or personal relationship that they hador have, at the time of drafting or submitting the article,with persons or institutions, and which could give riseto a conflict of interest concerning the article submittedfor publication in the Cover Letter. Their declaration will appear in the printed journal (also see section “Acknowledgments”).
Obtaining of permissions.The authors are responsible for obtaining the correspondingpermission to partially reproduce material (text,tables, or figures) from other publications. These permissionsshould be requested from both the author and the publisherthat published said material. Permission to publish from theinstitution that financed the investigation is required.
A declaration that the content of the article is originaland that it has not been previously published or sent forconsideration to any other publication, either totally orpart of it must be made. The authors should be aware thatnot declaring that the material submitted for publicationhas already been totally or partially published is a serious violation of scientific ethics.Furthermore, authors who usepreviously published material in their article (text, tablesor figures) are responsible for obtaining the pertinent permissions for its reproduction in the journal. The authorsshould have obtained written authorization both from theauthor and from publishing company that has published thematerial in question and submit a copy of this permissiontogether with the article to the Journal.
Redundant or duplicated publication.The journal will not accept previously published materialand will not consider manuscripts for publication that aresimultaneously submitted to other journals or redundant orduplicated publications, that is, articles that are substantiallythe same as another already published one, whether printedor electronicallyin peer reviewed journals. The authors should state in the cover letter whether the same article has been submitted or publishedin part or in its entirety, an action that could be consideredredundant or duplicate publication.These restrictions are not applicable to the summaries published of communications, speeches, or lectures presented in national and international scientific meetings or working papers.It is necessary toinclude references to these prior publications in the cover letter. Infectio follows the recommendations of Committee on Ethics Publication (COPE) on this topic.
General presentation of the manuscript
The manuscripts must be written in Spanish or English, in paper format with size DIN-A4 pages, double spaced witha (Arial font, letter type of 12 characters per inch). Abbreviations will be introduced after the complete termit represents when it is first used in the article, except inthe title. The metric international system (periods for thousands, comma for decimals) should be preferred but the anglosaxon system is also permitted (comma for thousands, periods for decimals), however the use of either system should be consistent through the text. Chemical, clinical and biological units should be defined strictly. The following data will be presented in the order givenhere:
a) First page: title of the article (in Spanish and in English), shorttitle of a maximum of 50 characters, full name and one orboth surnames (joined by a hyphen) of the authors, placeof work (institution, department, city and country). It willstate whether there was any grant or financial support.The academic degrees or position of authors should not be included. It will contain the statement by each one of the authorson whether or not there are conflicts of interest. It will include the full name, e-mail address, telephoneand fax number, and full postal address of the author forcorrespondence, who will also be responsible for correctingthe proofs. The first page must be submitted in a separatefile from the rest of the manuscript.
b)Second Page; Abstract and Key WordsThey must be attached in Spanish and in English. The abstract should follow the recommendations of each specific section. That of originals will be structured into the following sections: “Objective”,mentioning the basic purpose of the work; “Material and method”, explaining the design of the study, the evaluationcriteria of the diagnostic tests and the temporal direction(retrospective or prospective), it will mention the patientscreening procedure, the inclusion criteria, and the numberof patients who started and finished the study; “Results”,will mention the most relevant and significant results of thestudy, as well as their statistical evaluation; “Conclusions”,those which are directly supported by the data will bementioned here, together with their clinical applicability;the same emphasis must be given to positive and negativefindings with similar scientific interest.At the end of the abstract here must be 3 to 10 key words,in accordance with these included in the Medical SubjectHeadings (MeSH) of Index Medicus/MEDLINE, available inEnglish at: http://www.nlm.nih.gov/mesh/meshhome.htmland translate them to Spanish.
Page three and onwards; the text
a) Introduction. It will be brief and must only give the information necessary so that the reader understands thetext that follows next. It will give the intention and the
fundamentals of the investigation. It must not containtables or figures. In a last paragraph it must clearly statethe objective/s of the study. Only quote references thatare strictly necessary.
b) Material and methods. The material used in the study will be mentioned; human or experimental, itscharacteristics, selection criteria and techniquesemployed, giving the necessary literature or direct data,so that the experiment could be repeated by the reader:it will mention compliance to good clinical practice andanimal experimentation guidelines. The name of patients should not be mentioned. Generic names instead of commercial names of drugs should be used. A short description of the ethical guidelines followed by the investigators in studies onhumans as well as on animals will be given. Studies onhumans must have the express approval of the localethics and clinical trials committee, and this must bementioned in the manuscript including the date and number of act of the Ethics or Institutional Board review Commission (see “Obligations of theauthor”).
c) Results. The observations made with the methodemployed are stated, not interpreted. These data will beshown in the text accompanied by tables and figures.
d) Discussion. The authors have to express their own opinions on the topic. Mentioning here the significance andpractical application of the results; considerations onthe possible inconsistency of the methodology and thereasons why the results may be valid; the relationshipwith similar publications and comparison between areasof agreement and disagreement, and the indicationsand the lines for future investigations. On the otherhand, it should be ensured that the discussion doesnot become a review on the subject and that conceptsalready expressed in the introduction are not repeated.The results of the study should not be repeated hereeither. The conclusions of the study will be expressed ina final paragraph of the discussion.
e) Acknowledgements. Only the persons or entities who havenotably contributed to make the work possible should bementioned: a) contributions that must be acknowledgebut do not justify being included as an author, and b) theacknowledgement for technical help must be recognized in a separate paragraph. All those mentioned specifically to their inclusion in this section.
f) Bibliography. References that are considered importantand have been read by the authors will only be included,and the number must not exceed the maximum allowedfor each section of the Journal. All references mustbe mentioned in the text consecutively according tothe order of appearance, and identified using Arabicnumerals in superscript. The references cited only in tables should be numbered according to the first identification of such table on the text. References should appear before the period or comma. The literature references must rigorously follow thereference format and style of the Uniform Requirementsfor Manuscripts Submitted to Biomedical Journals,available at: http://www.icmje.org/. They will be set out on a separate page, in order of appearance in thetext. Non peer reviewed references such as from meeting minutesor working papers are not acceptable as literature references. It will notinclude references of articles subject to examination.Accepted papers in press can be cited by including their DOI. For examples of the formats of literature references, theauthors can consult the web page:
http://www.nlm.nih.gov/bsd/uniform_requirements.html.
Non-compliance to these requirements could lead to the rejection of thework for publication.
Original article: Surnames and initials of all the authors, when thereare six or less, They should be followed by the expression “et al” if thereare seven or more authors. When indicating theinitial and final pages of a document only the digits thatdiffer from the initial page must be included (e.g., 34-9, andnot 34-39; 136-41 and not 136-141). Thejournal names must be abbreviated according to the styleused in Index Medicus (List of Journals Indexed included in theJanuary edition of Index Medicus and on the website of theNLM library: http://www.nlm.nih.gov). Examples:
- Lessthansixauthors:González A, Estrada S, Álvarez H. Resistencia primaria a los medicamentos antituberculosos en pacientes VIH positivos y pacientes VIH negativos con tuberculosis en Medellín Colombia. Infectio. 2001;5:223-34.
- More than six authors: Velásquez S, Matute JD, Gámez LY, et al. Characterization of nCD64 expression in neutrophils and levels of s-TREM-1 and HMGB-1 in patients with suspected infection admitted in an emergency department. Biomedica. 2013;33:643-52.
- Electronic journal: Bility MT, Cheng L, Zhang Z, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and m2-like macrophages. PLoSPathog. 2014;10(3):e1004032. doi:10.1371/journal.ppat.1004032.
- Journal supplement: Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand. 1996;67 Suppl 219:29–33.
- Books: Auwels F. Atlas zurBiomechanik der gesunden und krankenHu’fte. Wurzburg: Springer Verlag; 1973.
- Book’s Chapter:Denis K, Kennett RH, Kinman N, Molinario C, Sherman L.Defining the B-cell repertoire with hybridomas derivedfrom monoclonal fragment cultures. In: Kennett RH,McKearn TJ, Bechtol KB, editors. Monoclonal antibodies.Hybridomas: a new dimension in biological analyses. 2ndEd. New York: Plenun Press; 1981. pp. 49-59.
- Doctoral thesis: García-Rueda FJ. Alteraciones del osteoclasto en la enfermedad de Paget [tesis doctoral], Salamanca, Universidad de Salamanca, 1987.
- Technicalreport: Dirección General para las Drogodependencias y Adicciones. Catálogo de los servicios asistenciales de los centros de tratamiento ambulatorio de Andalucía. Sevilla: Junta de Andalucía; 2003.
Tables.
They will be presented on separate sheetswithin the text file and numbered with Arabic numbers in order of appearance (example, table 1). If a table occupiesmore than one page, the headings will be repeated onthe following page. Acronyms and abbreviations must also beaccompanied with an explanatory legend at the foot. Thejournal will admit tables that will occupy a maximum ofone printed page. The statistical significance level shouldbe mentioned at the foot of the table, if it has not beenincluded in the text of the table.
a) Figure footnotes. The footnote will include a sufficientlyexplanatory title with the need to refer to the text. Whensymbols, arrows, numbers or letters are used, they mustbe clearly explained in the legend. For the explanatoryfootnotes lower case letters in superscript and inalphabetical order (a, b, c…) will be used.
Figures
All graphs, drawings and photographs will be consideredas figures and must be downloaded in the EES separatelyfrom their footnotes, which will be included in the text file,at the end of the references. Each figure will be presentedon a separate sheet and identified by consecutive Arabicnumerals, corresponding to their order of appearance inthe text (for instances, fig. 1). In case of many images in a same figure these should identified by a number a letter (for instances, fig 1a, fig. 1b, fig 1c). Theresolution of the images must be a minimum of 300 dotsper inch. Photographs may be submitted in colour for theirreproduction in the electronic edition of the Journal; they willappear in black and white in the printed version. Images thatmay contain identifiable persons will be suitably maskedand, if the face needs to be shown, their written permissionmust be available (see “Obligations of the author”). Inphotographs of histological preparations it must mentionthe type of stain used and the magnification at the end of thetext (e.g., HE, 100 X). Whenever necessary, graph resourceswill be used (arrows, asterisks) to highlight the essentialpart of the image. Initials and abbreviations must always beaccompanied by an explanatory footnote.
Any graphic, text or table material published previously should be accompanied of the written permission to be published in Infectio, authors are responsible to obtain such permissions from authors and editorials.
Confirmation by coauthors of submitted version
It is responsibility of each co-author to know the version submitted. Each coauthor will receive an email at the moment to be downloaded the manuscript in the Scholar One Manuscriptplatform by the corresponding author.
Guarantees and transfer of intellectual property rights
The text relative to the guarantees a transfer of copyrightare reproduced below:
1. The submission of your text by this medium, including graphs, designs or illustrations (hereinafter, genericallycalled “Works”) on the Scholar One Manuscriptplatform will assume the acceptance of thefollowing conditions:
– The author guarantees that the Works sent for publication in this Journal, or anyother products arising from the same, are originals,unpublished and of their authorship, and that thesehave not been published previously or submittedsimultaneously to any other publisher for their publication.
– Likewise, the authors guarantee under their responsibility, that they hold all the exploitation rightsof the Works, that in no case do these damage third parties and that, in the event that there are exploitationrights of third parties, the author has obtainedthe appropriate authorisation to exploit them andauthorises their exploitation by ACIN.
– Likewise, author guarantees that the Works sent to Infectiodo not comply with regulations onthe protection of personal data. In particular, he/sheguarantees having obtained the written previous authorization and previous consent of the patientsor their families for their publication, in the eventthat these patients may be identified in the Works orwhen the published information makes them easilyidentifiable.
2. Transfer of exploitation rights. The author exclusively transfers to the AsociaciónColombiana de Infectología(ACIN), with authority of transfer to third parties, allthe exploitation rights arising from the Works whichmay be accepted for publication in the Journal, aswell as any other products derived from these, and inparticular those of reproduction, distribution, publiccommunication (including interactive on demand) andtransformation (including adaptation, modification, andwhere applicable their translation), for all the exploitationmodalities (including, but not limited to: paper format,electronic format, on-line computer or audio-visualsupport, as well as any other format, including forpromotional and publicity purposes and/or for makingderived products), throughout the world and for the legalduration of the rights as set out in the current RevisedText of the Intellectual Property Law. As a result, theauthor will not be able to publish or distribute the Worksthat may be selected for their publication in the Journal,neither wholly or partially, nor be able to authorise theirpublication to third parties, without the mandatoryprevious written approval of the ACIN.
Editorial process
The author, using the record number which will bereceived with the acknowledgement of receipt, will be ableto track the status of evaluation of his/her article Scholar One Manuscript. The editor in Chief will designate an Associate Editor which will be responsible to designate at least two reviewers and to communicate with the corresponding author. The evaluation process takes between one to three months. The Associate Editor will take the decision after reception of the evaluation by reviewers about acceptation, review with minor or major changes or refusal. The decision and the reviewers report will be sent to corresponding author.
Whenever the Editorial Committee indicates makingminor changes to the articles, the authors must submit thenew version via the Scholar One Manuscriptwithin a maximum of 3 months, together with a letter, written in the “Response toReviewers” section, in which it will explain indetail the changes made, given in response to the reports of the reviewers.No article will be accepted infinal form until all the corrections have been satisfactorilymade. New rounds of evaluation,as needed, could be requested until the Associate Editor consider that a definitive decision can be made.
The Editorial Committee reserves the right to rejectarticles that it judges to be inappropriate, as well asto introduce changes in style and /or shorten texts if sorequired, promising to respect the contents of the original.
When it is accepted, the author for correspondence willreceive print proofs for their correction when the articleis ready for print, which must be returned to the EditorialTeam within 48 hours of receiving them. These print proofs are for the purpose of detecting typing, spelling orformatting errors. Corrections that affect the content orchange the article in its original form will not be accepted. If these proofs are not received by the Editorial teamwithin the time set, the Editorial Committee will not beheld responsible for any errors or omissions that could be published.
The Editorial Committee reserves the right on whetheror not to accept the corrections made by the author in theprint proofs.
The Editorial Committee and the ACIN will not be held responsible for the concepts,opinions or assertions made by the authors in their articles. |
|
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License